Prof Andrew Scott AM
(MB BS Hons, MD, FRACP, FAHMS, FAANMS, FAICD, DDU)
Head, Tumour Targeting Program, Olivia Newton-John Cancer Research Institute
Austin Health
La Trobe University
University of Melbourne
Prof Andrew Scott leads the Tumour Targeting Program at the Olivia Newton-John Cancer Research Institute and co-Director, Centre for Research Excellence in Brain Tumours; is Director, Department of Molecular Imaging and Therapy, Austin Health; is Research Translation and Commercialisation Lead of the Victorian Comprehensive Cancer Centre (VCCC); and is Professor, University of Melbourne and La Trobe University.
His clinical and research interests are focused on developing innovative strategies for targeted therapy of cancer (particularly with monoclonal antibodies and peptides), molecular imaging in oncology, and global advocacy in Oncology and Nuclear Medicine. His laboratory has been involved in the preclinical development and first-in-man trials of numerous recombinant antibodies in cancer patients, and seven antibodies developed in his laboratory have been licenced to Biotech and Pharma companies, and have entered Phase I/II/III trials.
He has published 470 peer reviewed papers and 27 book chapters, is an inventor on 25 patents, and is a founder of a biotech company. Prof. Scott is a member of the Strategic Advisory Committee for the National Imaging Facility (NIF), a member of the Scientific Committee of ARTnet, and Federal Council member of the Australian and New Zealand Society of Nuclear Medicine. He is an elected Fellow of the Australian Academy of Health and Medical Sciences, the US Society of Nuclear Medicine (SNMMI), and the International Society for Strategic Studies in Radiology (IS3R).
Current Projects & Areas of Interest:
Preclinical and clinical research of brain cancer biology and therapeutic targeting
ErbB family, including novel drugs against tumour specific, conformation targets
Tumour microenvironment targeting, especially EphA3 and FAP targeting drugs
Imaging of brain cancer using molecular imaging and MRI, including novel drug imaging and biodistribution
Clinical trials for novel drugs for patients with primary brain cancer
Both industry and investigator initiated clinical trials